When the cancer patients were divided into control (⩽10 mg l−1) and acute-phase response (>10 mg l−1) groups based on the upper normal limit of serum CRP, those in the acute-phase group had an average 30% reduction in drug metabolism (0.070±0.024 vs 0.049±0.022 min−1, respectively). Here, CRP is linked to cancer.